Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 0.45 |
| ▸ | GSK3B | P49841 | 9/20 | 0.45 |
| ▸ | CLK2 | P49760 | 3/20 | 0.45 |
| ▸ | CLK3 | P49761 | 3/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29925262 | 1.00 | DYRK1A (0.45) | DYRK1AGSK3BCLK2CLK3LRRK2 | |
| SCHEMBL29925784 | 0.82 | DYRK1A (0.44) | DYRK1AGSK3BCLK2CLK3LRRK2 | |
| SCHEMBL29925212 | 0.81 | DYRK1A (0.43) | DYRK1AGSK3BCLK2CLK3LRRK2 | |
| SCHEMBL27031760 | 0.81 | DYRK1A (0.43) | DYRK1AGSK3BCLK2CLK3LRRK2 | |
| SCHEMBL24012781 | 0.76 | GSK3B (0.35) | DYRK1AGSK3BCLK2CLK3LRRK2 | |
| SCHEMBL30242435 | 0.76 | GSK3B (0.35) | DYRK1AGSK3BCLK2CLK3LRRK2 | |
| SCHEMBL29925496 | 0.75 | GSK3B (0.39) | DYRK1AGSK3BCLK2CLK3LRRK2 | |
| SCHEMBL29925849 | 0.75 | GSK3B (0.39) | DYRK1AGSK3BCLK2CLK3LRRK2 | |
| SCHEMBL27031843 | 0.75 | GSK3B (0.39) | DYRK1AGSK3BCLK2CLK3LRRK2 | |
| SCHEMBL27031742 | 0.75 | GSK3B (0.39) | DYRK1AGSK3BCLK2CLK3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | claimed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | claimed |
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PARK7, PINK1 | DYRK1A 993/4885GSK3B 120/4885CLK2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.